Chemomab Therapeutics LtdNASDAQ:CMMB
- LAST PRICE1.2700
- TODAY'S CHANGE (%)0.0800 (6.7227%)
- Bid / Lots1.2100/ 2
- Ask / Lots1.2900/ 34
- Open / Previous Close1.3400 / 1.1900
- Day Range
- 52 Week Range
- Volume197,215
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CMMB |
|---|---|---|
| 09:32 ET | 6316 | 1.278 |
| 09:34 ET | 3079 | 1.2403 |
| 09:36 ET | 2511 | 1.3 |
| 09:38 ET | 100 | 1.2401 |
| 09:39 ET | 200 | 1.2999 |
| 09:41 ET | 6639 | 1.285 |
| 09:43 ET | 4524 | 1.2819 |
| 09:45 ET | 10270 | 1.2991 |
| 09:48 ET | 2100 | 1.3 |
| 09:50 ET | 6478 | 1.3093 |
| 09:52 ET | 6600 | 1.2801 |
| 09:54 ET | 16795 | 1.3215 |
| 09:56 ET | 1200 | 1.3299 |
| 09:57 ET | 2175 | 1.3 |
| 09:59 ET | 100 | 1.3295 |
| 10:01 ET | 7912 | 1.29 |
| 10:03 ET | 1200 | 1.3294 |
| 10:08 ET | 1800 | 1.3012 |
| 10:10 ET | 420 | 1.29 |
| 10:12 ET | 800 | 1.3299 |
| 10:15 ET | 330 | 1.3212 |
| 10:17 ET | 100 | 1.3 |
| 10:19 ET | 900 | 1.3 |
| 10:21 ET | 6249 | 1.305 |
| 10:24 ET | 100 | 1.3156 |
| 10:26 ET | 120 | 1.3053 |
| 10:28 ET | 100 | 1.3199 |
| 10:35 ET | 3341 | 1.31 |
| 10:39 ET | 12643 | 1.3106 |
| 10:42 ET | 323 | 1.3121 |
| 10:44 ET | 100 | 1.32 |
| 10:46 ET | 6616 | 1.3 |
| 10:55 ET | 1490 | 1.28 |
| 11:09 ET | 100 | 1.2608 |
| 11:20 ET | 100 | 1.25 |
| 11:22 ET | 207 | 1.2415 |
| 11:24 ET | 600 | 1.25 |
| 11:26 ET | 1538 | 1.23 |
| 11:29 ET | 1000 | 1.24 |
| 11:33 ET | 1160 | 1.24 |
| 11:44 ET | 100 | 1.25 |
| 11:47 ET | 900 | 1.25 |
| 11:54 ET | 1980 | 1.25 |
| 11:56 ET | 100 | 1.26 |
| 12:03 ET | 2168 | 1.27 |
| 12:14 ET | 1000 | 1.3038 |
| 12:18 ET | 110 | 1.31 |
| 12:21 ET | 149 | 1.2952 |
| 12:23 ET | 600 | 1.2801 |
| 12:25 ET | 100 | 1.3099 |
| 12:32 ET | 5500 | 1.3 |
| 12:34 ET | 761 | 1.3 |
| 12:52 ET | 7532 | 1.3 |
| 01:01 ET | 1200 | 1.3 |
| 01:28 ET | 700 | 1.2998 |
| 01:32 ET | 947 | 1.285 |
| 01:33 ET | 300 | 1.2799 |
| 01:35 ET | 900 | 1.27 |
| 01:37 ET | 3131 | 1.28 |
| 01:46 ET | 500 | 1.2819 |
| 01:55 ET | 948 | 1.2816 |
| 02:27 ET | 100 | 1.2971 |
| 02:31 ET | 100 | 1.2971 |
| 02:47 ET | 300 | 1.29 |
| 03:03 ET | 8250 | 1.28 |
| 03:09 ET | 3300 | 1.28 |
| 03:18 ET | 234 | 1.2801 |
| 03:20 ET | 234 | 1.29 |
| 03:36 ET | 500 | 1.2844 |
| 03:45 ET | 100 | 1.2848 |
| 03:48 ET | 200 | 1.28 |
| 03:50 ET | 14865 | 1.245 |
| 03:52 ET | 500 | 1.28 |
| 03:54 ET | 337 | 1.25 |
| 03:57 ET | 663 | 1.27 |
Today
Yesterday
Chemomab Therapeutics Announces $10 Million Private Placement, from 7:38AM ET on Thursday Jul 25, 2024 by Dow Jones
7:38AM ET on Thursday Jul 25, 2024 by Dow JonesPress Release: Chemomab Therapeutics Announces $10 Million Private Placement, from 7:38AM ET on Thursday Jul 25, 2024 by Dow Jones
7:38AM ET on Thursday Jul 25, 2024 by Dow JonesChemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis, from 7:00AM ET on Thursday Jul 25, 2024 by Dow Jones
7:00AM ET on Thursday Jul 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Chemomab Therapeutics Ltd | 16.9M | 0.0x | --- |
CytoMed Therapeutics Ltd | 22.7M | -6.2x | --- |
Sensei Biotherapeutics Inc | 17.0M | -0.5x | --- |
Indaptus Therapeutics Inc | 17.3M | -1.2x | --- |
Edesa Biotech Inc | 16.4M | -2.3x | --- |
Conduit Pharmaceuticals Inc | 17.9M | -7.2x | --- |
Company Information
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Contact Information
- Headquarters
- Kiryat Atidim, Building 7TEL AVIV-YAFO, Israel 6158002
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Nissim Darvish
- Chief Executive Officer, Director
- Adi Mor
- Chief Financial Officer
- Sigal Fattal
- Chief Medical Officer, Vice President - Drug Development
- Matthew Frankel
- Independent Director
- Neil Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 14.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $-26.80 |
Book Value | $23.93 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
